Get the Stockscreener App
33.89
1.60%
-0.55
Indivior Pharmaceuticals Inc stock is traded at $33.89, with a volume of 1.50M.
It is down -1.60% in the last 24 hours and up +2.85% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease.
See More
Previous Close:
$34.44
Open:
$34.61
24h Volume:
1.50M
Relative Volume:
0.68
Market Cap:
$4.24B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
3,389.00
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
-2.00%
1M Performance:
+2.85%
6M Performance:
+40.33%
1Y Performance:
+276.97%
1-Day Range:
$33.85
$34.94
1-Week Range:
$33.84
$35.57
52-Week Range:
$7.62
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
234 BATH ROAD, SLOUGH, BERKSHIRE
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
33.89 | 4.31B | 1.12B | 5.00M | -383.00M | 0.01 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.66 | 58.95B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.78 | 53.73B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.27 | 49.47B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.22 | 39.98B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.42 | 20.69B | 3.13B | 1.27B | 1.12B | 26.39 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Setup Case - ChartMill
Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? - The Globe and Mail
Indivior Pharmaceuticals, Inc. (INDV) Investor Outlook: Navigating a 34.59% Potential Upside - DirectorsTalk Interviews
VELA International Fund's Indivior Pharmaceuticals Inc(INDV) Holding History - GuruFocus
Analysts Offer Insights on Healthcare Companies: Indivior (INDV) and NeoGenomics (NEO) - The Globe and Mail
New York State Common Retirement Fund Sells 56,140 Shares of Indivior PLC $INDV - MarketBeat
Indivior Pharmaceuticals (INDV) Stock Analysis: A 30% Upside Opportunity Amidst Promising Drug Innovations - DirectorsTalk Interviews
Jackson Creek Investment Advisors LLC Buys Shares of 60,890 Indivior PLC $INDV - MarketBeat
Federated Hermes Inc. Makes New $8.12 Million Investment in Indivior PLC $INDV - MarketBeat
How Opvee, Indivior’s powerful overdose antidote, went bust - statnews.com
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ - The Manila Times
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on ... - Caledonian Record
Indivior’s Stock Under Pressure: Can the Addiction-Treatment Specialist Regain Investor Trust? - AD HOC NEWS
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum Breakout Setup - Chartmill
Will Indivior’s (INDV) US Headquarters Shift and Larger ESOP Shelf Reshape Its Corporate Narrative? - simplywall.st
Indivior completes redomiciliation from UK to US By Investing.com - Investing.com Nigeria
Aug PreEarnings: Is Indivior PLC vulnerable to short sellersQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Indivior announces completion of redomiciliation to U.S. - TipRanks
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq - GuruFocus
Indivior Completes U.S. Domestication and Governance Realignment - TipRanks
Indivior Announces Completion of Redomiciliation to the United States - The Manila Times
Indivior completes redomiciliation from UK to US - Investing.com
Indivior Signs Note Purchase Agreement Amendment With Piper Sandler Finance - TradingView
Indivior PLC: Can a Focused Addiction-Treatment Portfolio Power the Next Wave of Growth? - AD HOC NEWS
Is Indivior PLC forming higher highs and higher lowsJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - mfd.ru
(INDV) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VELA Investment Management LLC Raises Stock Position in Indivior PLC $INDV - MarketBeat
Indivior’s 2026 Revenue Guidance Tightens Expectations Might Change The Case For Investing In Indivior (INDV) - Yahoo Finance
Indivior PLC (INDV) Investor Outlook: A 35.66% Potential Upside With Strong Buy Ratings - DirectorsTalk Interviews
Aug Selloffs: Can Indivior PLC stock outperform in a bear marketJuly 2025 Technicals & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Indivior PLC: Can a Focused Addiction-Treatment Specialist Win the Next Decade of Mental Health Phar - AD HOC NEWS
Grail and Indivior PLC come out on top in healthcare quant picks ahead of Q4 earnings - MSN
Ritholtz Wealth Management Buys Shares of 92,845 Indivior PLC $INDV - MarketBeat
Market Wrap: Will WNEB outperform small cap indexes2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
Short Interest in Indivior PLC (NASDAQ:INDV) Rises By 57.5% - MarketBeat
Indivior (NASDAQ:INDV) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
Indivior PLC: How a Specialist Addiction Franchise Is Quietly Rebuilding a Global Pharma Contender - AD HOC NEWS
Indivior (INDV) Price Target Increased by 13.21% to 43.71 - Nasdaq
Q1 Earnings Forecast for Indivior Issued By HC Wainwright - MarketBeat
Portfolio Update: Is now the right time to enter Indivior PLCJuly 2025 Chart Watch & Accurate Entry/Exit Alerts - baoquankhu1.vn
Indivior PLC (INDV) Stock Analysis: Exploring a 24% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Aug Setups: Does Indivior PLC stock trade at a discount to peersMarket Activity Summary & Safe Capital Growth Tips - Bộ Nội Vụ
Risks Report: Will Indivior PLC stock remain a Wall Street favorite2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
HC Wainwright Estimates Indivior's Q2 Earnings (NASDAQ:INDV) - MarketBeat
51,426 Shares in Indivior PLC $INDV Purchased by KLP Kapitalforvaltning AS - MarketBeat
Volume Recap: Is Indivior PLC forming higher highs and higher lows2025 Market Sentiment & Verified Entry Point Signals - baoquankhu1.vn
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus - Yahoo Finance
Indivior stock price target raised to $48 from $35 at H.C. Wainwright - Investing.com Nigeria
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Ratin - GuruFocus
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Indivior Pharmaceuticals Inc Stock (INDV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Humphreys Keith | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
5,802 |
| NINIVAGGI DANIEL A | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,923 |
| Stejbach Mark | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,847 |
| Wheadon David E. | Director |
Jan 05 '26 |
Buy |
35.39 |
1,771 |
62,680 |
14,395 |
0.98%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):